lonafarnib has been researched along with piperidines in 190 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (piperidines) | Trials (piperidines) | Recent Studies (post-2010) (piperidines) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 40,235 | 5,221 | 14,545 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (5.26) | 18.2507 |
| 2000's | 107 (56.32) | 29.6817 |
| 2010's | 56 (29.47) | 24.3611 |
| 2020's | 17 (8.95) | 2.80 |
| Authors | Studies |
|---|---|
| Bishop, WR; Bryant, MS; Catino, JJ; Chen, J; Dell, J; Doll, RJ; Ferrari, E; Girijavallabhan, VM; Korfmacher, WA; Lee, S; Lin, CC; Lipari, P; Liu, M; Malkowski, M; Mallams, AK; Nielsen, L; Njoroge, FG; Nomeir, AA; Prioli, N; Remiszewski, S; Sinha, D; Syed, J; Taveras, AG; Wang, L; Yaremko, B | 1 |
| Afonso, A; Alvarez, CS; Bishop, WR; Connolly, M; Cooper, AB; del Rosario, J; Desai, J; Deskus, J; Ganguly, AK; Kelly, J; Kirschmeier, P; Liu, YT; Mallams, AK; Njoroge, FG; Patton, R; Pinto, P; Rane, DF; Remiszewski, S; Rossman, RR; Taveras, AG; Vibulbhan, B; Wang, J; Wang, L; Wolin, R; Wong, J | 1 |
| Lavelle, F | 1 |
| Bishop, WR; Izbicka, E; Lawrence, RA; Petit, T; Von Hoff, DD; Weitman, S | 1 |
| Albanese, MM; Alvarez, CS; Cesarz, D; del Rosario, J; Deskus, J; Doll, RJ; Ganguly, AK; Girijavallabhan, VM; Le, HV; Mallams, AK; Njoroge, FG; Piwinski, JJ; Remiszewski, S; Rossman, RR; Strickland, CL; Taveras, AG; Vibulbhan, B; Weber, PC; Windsor, WT; Wu, Z | 1 |
| Kim, H; Likhari, P; Lin, CC; Nomeir, AA | 1 |
| Afonso, A; Bishop, WR; James, L; Kelly, J; Weinstein, J | 1 |
| Afonso, A; Alvarez, C; Bishop, WR; Carr, D; Chao, J; del Rosario, J; Deskus, J; Doll, RJ; Ganguly, AK; Girijavallabhan, VM; Heimark, L; James, L; Kirschmeier, P; Lalwani, T; Liu, M; Mallams, AK; Njoroge, FG; Pinto, P; Pramanik, B; Remiszewski, S; Rossman, RR; Taveras, AG; Vaccaro, CJ; Vibulbhan, B; Wang, L | 1 |
| Bishop, WR; Chen, J; Ferrari, E; Gurnani, M; Hajian, G; Lipari, P; Liu, M; Malkowski, M; Nielsen, LL; Shi, B; Yaremko, B | 1 |
| Adjei, AA; Atherton, P; Bishop, WR; Cutler, DL; Davis, JN; Erlichman, C; Hanson, LJ; Kaufmann, SH; Kirschmeier, P; Marks, RS; Sloan, JA; Svingen, PA | 1 |
| Armstrong, L; Ashar, HR; Bishop, WR; Black, S; Carr, D; Gray, K; James, L; Kirschmeier, P | 1 |
| Adjei, AA; Davis, JN; Erlichman, C; Kaufmann, SH; Svingen, PA | 1 |
| Dodds, DR; Girijavallabhan, VM; Jain, R; Liu, J; Megati, S; Morgan, B; Njoroge, FG; Zaks, A | 1 |
| Armstrong, L; Ashar, HR; Bishop, WR; Black, S; Carr, D; Doll, RJ; Gray, K; James, L; Kirschmeier, P; Maxwell, E; McGuirk, M; Taveras, AG | 1 |
| Bishop, WR; Hajian, G; Liu, M; Nielsen, LL; Shi, B; Terracina, G; Yaremko, B | 1 |
| Awada, A; Cutler, DL; de Jonge, MJ; Eskens, FA; Faber, MN; Hanauske, AR; Luyten, GP; Piccart, M; Sparreboom, A; Statkevich, P; Verweij, J | 1 |
| Daley, GQ; Groffen, J; Heisterkamp, N; Reichert, A | 1 |
| Bishop, WR; Choe, K; Daley, GQ; Gerlach, MJ; Hoover, RR; Kirschmeier, P; Koh, EY; Peters, DG; Zhang, H | 1 |
| Glass, TL; Liu, TJ; Yung, WK | 1 |
| Adjei, AA; Bruzek, LM; Davis, JN; Erlichman, C; Kaufmann, SH | 1 |
| Feldkamp, MM; Guha, A; Lau, N; Roncari, L | 1 |
| Doll, RJ; Ganguly, AK; Girijavallabhan, VM | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Adjei, AA; End, DW; Karp, JE; Kaufmann, SH; Lancet, JE; Wright, JJ | 1 |
| Bernard, C; Chen, F; Poirier, M; Wong, YS; Wu, GG | 1 |
| Bernhard, E; Hahn, SM; McKenna, WG | 1 |
| Bishop, WR; Brassard, DL; English, JM; Kirschmeier, P; Malkowski, M; Nagabhushan, TL | 1 |
| Daley, GQ; Hoover, RR; Mahon, FX; Melo, JV | 1 |
| Adjei, AA; Dy, GK; Haluska, P | 1 |
| Baum, C; Hollywood, E; Ilson, D; Kelsen, DP; Kemeny, N; O'Reilly, E; Saltz, LB; Sharma, S; Statkevich, P; Zaknoen, S; Zhu, Y | 1 |
| Aki, C; Chao, J; Doll, RJ; Girijavallabhan, V; Hollinger, F; James, L; Kirschmeier, P; Lalwani, T; Liu, M; Nomeir, A; Patton, R; Snow, M; Strickland, CL; Taveras, AG; Weber, P; Windsor, WT | 1 |
| Dancey, JE | 1 |
| Caponigro, F | 1 |
| Awada, A; Bleiberg, H; Cutler, DL; Eskens, FA; Faber, MN; Fumoleau, P; Piccart, M; Statkevich, P; van der Gaast, A; Verweij, J; Wanders, J | 1 |
| Adjei, AA; Dy, GK | 1 |
| Bishop, WR; Ganguly, AK; Girijavallabhan, V; Kirschmeir, P; Njoroge, FG; Pinto, P; Strickland, CL; Vibulbhan, B | 1 |
| Baum, C; Kirschmeier, P | 1 |
| Brodsky, AL | 1 |
| Kelland, LR | 1 |
| Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T | 1 |
| Druker, BJ | 1 |
| Eisen, TG; Smalley, KS | 1 |
| Baum, CM; Kirschmeier, P; Taveras, AG | 1 |
| Bernard, C; Chen, F; Hou, D; Kim-Meade, A; Kuo, SC; Levy, S; Liu, J; Wu, GG | 1 |
| Chun, KH; Hassan, K; Hong, WK; Khuri, F; Lee, HY; Lotan, R | 1 |
| Brisson, JM; Hsieh, Y; Korfmacher, WA; Merkle, K; Wang, G | 1 |
| Cortes, J | 1 |
| Groffen, J; Heisterkamp, N; Mishra, S; Zhang, B | 1 |
| de Bono, JS; Rowinsky, EK; Tolcher, AW | 1 |
| Johnson, WW; Wang, EJ | 1 |
| Ardizzoni, A; De Cupis, A; Favoni, RE; Loprevite, M; Mazzanti, P; Scolaro, T; Semino, C | 1 |
| Tauchi, T | 1 |
| Aggarwal, BB; Khuri, FR; Takada, Y | 1 |
| Jain, SR; Khuri, FR | 1 |
| Bangert, S; Bishop, WR; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Kies, MS; Kim, ES; Kirschmeier, P; Lu, C; Meyers, ML; Munden, RF; Papadimitrakopoulou, V; Shin, DM; Statkevich, P; Tendler, C; Thall, PF; Thompson, E; Wang, XM; Zhu, Y | 1 |
| Chen, QZ; Illgen, K; Keng, YF; Khazak, V; Lu, Y; Menon, SR; Sakamuri, S; Schabbert, S; Weber, L | 1 |
| Fu, H; Khuri, FR; Sun, SY; Wang, R; Zhou, Z | 1 |
| Kinsella, BT; O'Meara, SJ | 1 |
| Chang, YS; Chun, KH; Hassan, K; Hong, WK; Ji, L; Khuri, FR; Lee, HY; Lotan, R; Moon, H | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H | 1 |
| Buresh, A; Heaton, R; Kurtin, S; List, A; Perentesis, J; Rimsza, L; Sugrue, M | 1 |
| Béliveau, R; Cusson, MH; Desrosiers, RR; Turcotte, S | 1 |
| Bernhard, EJ | 1 |
| Helbig, G; Hołowiecki, J | 1 |
| Nestler, HP | 1 |
| Elhamri, M; Thomas, X | 1 |
| Abbruzzese, A; Budillon, A; Caponigro, F; Caraglia, M; Marra, M; Tagliaferri, P | 1 |
| Feldman, EJ | 2 |
| El-Naggar, A; Giannakakou, P; Hamel, E; Khuri, FR; Marcus, AI; Nivens, M; O'Brate, A; Wong, J; Yao, TP; Zhou, J | 1 |
| Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L | 1 |
| Adjei, AA; Bruzek, LM; Kaufmann, SH; Poynter, JN | 1 |
| Caponigro, F; Chollet, P; de Balincourt, C; Fiedler, W; Fumoleau, P; Geoffrois, L; Lacombe, D; Peters, GJ; Ravaud, A; Theodore, C; Vermorken, JB | 1 |
| Chu, Z; Khuri, F; Mao, L; Ren, H; Tai, SK | 1 |
| Appels, NM; Beijnen, JH; Rosing, H; Schellens, JH; van Maanen, MJ | 1 |
| Basso, AD; Bishop, WR; Kirschmeier, P; Liu, G; Long, BJ; Mirza, A | 1 |
| Fossella, FV; Glisson, BS; Khuri, FR; Kies, MS; Kim, ES; Munden, RF; Papadimitrakopoulou, V; Pisters, KM; Rogatko, A; Statkevich, P; Summey, C; Tighiouart, M; Zaknoen, S | 1 |
| Chen, J; David, E; Khuri, FR; Lonial, S; Sun, SY; Waller, EK | 1 |
| Poirier, M; Wong, Y; Wu, GG | 1 |
| Han, JY; Hong, WK; Kim, E; Lee, HY; Morgillo, F; Myers, JN; Oh, SH | 1 |
| Appels, NM; Beijnen, JH; Schellens, JH | 1 |
| Kurisu, K; Okamura, T | 1 |
| Borthakur, G; Cortes, J; Daley, G; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Sugrue, M; Talpaz, M | 1 |
| Cohen, P; El-Naggar, AK; Hong, WK; Khuri, F; Kies, M; Kim, JH; Kim, WY; Lee, HY; Myers, JN; Oh, SH; Younes, MN | 1 |
| Chowdhury, SK; Ghosal, A; Hapangama, N; Su, AD; Tong, W; Yuan, Y; Zbaida, S | 1 |
| Jiang, D; Zhang, M | 1 |
| Lee, HY; Morgillo, F | 1 |
| Baulch-Brown, C; Ma, D; Molloy, TJ; Spencer, A; Yeh, SL | 1 |
| Alton, KB; Chowdhury, SK; Feng, W; Ghosal, A; Su, AD; Tong, W | 1 |
| Kong, M; Lee, JJ | 1 |
| Bukowski, RM; Curtis, D; Frank, E; Lipton, A; Ready, NE; Statkevich, P; Zhu, Y | 1 |
| Harousseau, JL | 1 |
| El-Naggar, A; Giannakakou, P; Iaconelli, J; Khuri, FR; Marcus, AI; Nettles, JH; Prussia, A; Schafer-Hales, K; Snyder, JP | 1 |
| Equbal, T; Ravikumar, M; Silakari, O | 1 |
| Khuri, FR; Liu, X; Marcus, AI; Sun, SY; Yue, P; Zou, W | 1 |
| Azam, M; Cortes, J; Daley, GQ; Nardi, V; Raz, T | 1 |
| Berk, S; Gajewski, TF; Ho, AW; Kuna, T; Marks, RE; Robbel, C | 1 |
| Cortes, J; Daley, GQ; Ferrajoli, A; Jabbour, E; Kantarjian, H; Koller, C; O'Brien, S; Statkevich, P; Verstovsek, S; Zhu, Y | 1 |
| Banerjee, A; Belasco, JB; Blaney, SM; Boyett, JM; Broniscer, A; Frank, E; Geyer, JR; Goldman, S; Gururangan, S; Kieran, MW; Kirschmeier, P; Kun, LE; Onar, A; Packer, RJ; Phillips, P; Pollack, IF; Statkevich, P; Turner, CD; Yver, A; Zhu, Y | 1 |
| Basso, AD; Black, S; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Robert Bishop, W; Taylor, SA | 1 |
| Cutler, DL; Statkevich, P; Zhu, Y | 1 |
| Dowlati, A; Halmos, B; Kern, JA; Kluge, A; Nethery, D | 1 |
| Basche, M; Chow, LQ; Eckhardt, SG; Gore, L; Grolnic, S; Morrow, M; O'Bryant, CL; Schultz, MK | 1 |
| Bishop, WR; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Nale, L; Taylor, SA | 1 |
| Jin, Q; Khuri, FR; Kim, ES; Lee, HY; Oh, SH | 1 |
| Chen, G; Doll, RJ; Ganguly, AK; Girijavallabhan, VM; Liu, YH; Mirza, UA; Pramanik, BN | 1 |
| Bishop, JM; Charoenthongtrakul, S; Field, KA; Refaeli, Y | 1 |
| Barker, J; Colombat, P; Cortes, J; DeAngelo, DJ; Feldman, EJ; Frank, E; Guilhot, F; Holyoake, T; Kirschmeier, P; Lipton, JH; List, A; Loechner, S; Maloisel, F; Martinelli, G; Nielsen, JL; O'Brien, SG; Petersdorf, S; Reiffers, J; Roboz, GJ; Simonsson, B; Statkevich, P; Turner, AR; Zhu, Y | 1 |
| Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H | 1 |
| André, M; Bosly, A; Bron, D; Debusscher, L; El Housni, H; Martiat, P; Mineur, P; Ravoet, C; Robin, V; Soree, A | 1 |
| Lowe, SW; Mavrakis, KJ; Mills, JR; Pelletier, J; Silva, RL; Tam, W; Teruya-Feldstein, J; Wendel, HG; Zhu, H | 1 |
| Chen, B; Lee, MH; Pan, J; Su, CH; Sun, L; Xu, ZX; Yeung, SC; Zhao, R | 1 |
| Giannakakou, P; Gjyrezi, A; Khuri, FR; Tamanoi, F; Vos, CC; Yoshida, M; Zhou, J | 1 |
| Feng, L; Ginsberg, LE; Glisson, BS; Hanrahan, EO; Hong, WK; Khuri, FR; Kies, MS; Kim, ES; Tran, HT; Truong, MT | 1 |
| Bishop, WR; Hsieh, Y; Kirschmeier, P; Liu, G; Long, BJ; Marrinan, CH; Taylor, SA | 1 |
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Le Moulec, S; Loriot, Y; Soria, JC | 1 |
| Appels, NM; Beijnen, JH; Bolijn, MJ; Schellens, JH; Stephens, TC; van Eijndhoven, MA | 1 |
| Li, M; Liu, A; Liu, B; Luo, X; Yu, H; Zheng, H | 1 |
| Beck, D; Berger, A; Flaherty, K; Garbe, C; Gogel, J; Kulms, D; Lasithiotakis, K; Maczey, E; Mauthe, M; Meier, F; Niessner, H; Proikas-Cezanne, T; Schadendorf, D; Schaller, M; Schittek, B; Sinnberg, T; Toulany, M; Venturelli, S | 1 |
| Castaneda, C; Cutler, DL; Hurwitz, HI; Kaufmann, SH; Meadows, KL; Morse, MA; Petros, WP; Statkevich, P; Truax, R; Zhu, Y | 1 |
| Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY | 1 |
| Bender, L; Chanel-Vos, C; Escuin, D; Fanucchi, MP; Gal, A; Giannakakou, P; Harvey, RD; Kauh, J; Khuri, FR; Kutner, M; Marcus, A; Pan, L; Ramalingam, SS; Saba, N; Shin, DM | 1 |
| Crovella, S; De Leo, L; Decorti, G; Marcuzzi, A; Pontillo, A; Tommasini, A | 1 |
| Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ | 1 |
| Adjei, AA; Cutler, DL; Hurwitz, HI; Kaufmann, SH; Meadows, KL; Meyers, ML; Morse, MA; Petros, WP; Rosen, LS; Statkevich, P; Wong, NS; Zhu, Y | 1 |
| Kang, JH; Kim, ES; Kyu Woo, J; Lee, HY; Lee, OH; Oh, SH | 1 |
| Baumann, K; Belau, A; Burges, A; Canzler, U; du Bois, A; Gropp-Meier, M; Huober, J; Kreienberg, R; Meier, W; Rau, J; Richter, B; Schmalfeldt, B; Schröder, W; Sehouli, J; Stähle, A; Wimberger, P; Wollschlaeger, K | 1 |
| Morse, MA; Wong, NS | 1 |
| Bishop, WR; Cleveland, R; Correia, A; Fligor, B; Gerhard-Herman, M; Giobbie-Hurder, A; Gordon, CM; Gordon, LB; Huh, SY; Kieran, MW; Kleinman, ME; Liang, MG; Miller, DT; Nazarian, A; Neuberg, DS; Ploski, C; Quinn, N; Regen, A; Riley, S; Schwartzman, A; Smoot, LB; Snyder, BD; Sonis, A; Statkevich, P; Ullrich, NJ | 1 |
| Couzin-Frankel, J | 1 |
| Wadman, M | 1 |
| Awada, A; Beijnen, JH; Diéras, V; Govaerts, AS; Huitema, AD; Kerklaan, BM; Le Tourneau, C; Marreaud, S; Mergui-Roelvink, M; Milojkovic Kerklaan, B; Piccart-Gebhart, MJ; Rosing, H; Schellens, JH | 1 |
| Colman, H; Conrad, C; Gilbert, MR; Groves, M; Hsu, S; Kang, S; Levin, V; Liu, D; Liu, V; Puduvalli, V; Yuan, Y; Yung, WK; Yust-Katz, S | 1 |
| Jiang, K | 1 |
| Heyer, GL; King, AA | 1 |
| Cho, YJ; Giobbie-Hurder, A; Gordon, LB; Kieran, MW; Kleinman, ME; Miller, DT; Neuberg, D; Silvera, VM; Ullrich, NJ | 1 |
| Fernandes, PA; Moorthy, NS; Ramos, MJ; Sousa, SF | 1 |
| Chen, X; Fagin, JA; Johnson, LK; Knauf, JA; Makarewicz, JM | 1 |
| Zhou, S | 1 |
| Brazier, J; Brown, WT; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J | 1 |
| Hisama, FM; Martin, GM; Oshima, J | 1 |
| Ghosh, S; Raghunath, M; Sinha, JK | 1 |
| Li, Y; Peng, G; Qin, J; Sun, L; Wang, J; Xie, S; Zhong, D | 1 |
| Aminossadati, B; Bachmann, HS; Burges, A; du Bois, A; Hillemanns, P; Huober, J; Kimmig, R; Kuhlmann, JD; Meier, W; Schmalfeldt, B; Sehouli, J; Siffert, W; Wimberger, P; Wollschlaeger, K | 1 |
| Ai Thanda Han, M; Bishop, R; Canini, L; Cooper, SL; Cotler, SJ; Dahari, H; Glenn, JS; Haynes-Williams, V; Heller, T; Idilman, R; Keskin, O; Kleiner, DE; Koh, C; Pinto, P; Subramanya, G; Uprichard, SL; Winters, MA; Wolff, EF; Yurdaydin, C; Zhao, X | 1 |
| Bancke Laverde, BL; Beirao Junior, PS; Carvalho, VO; Celli, A; Cunico, C; Lucas de Mello, M; Santos Piedade, G | 1 |
| Cleveland, RH; D'Agostino, RB; Dowton, AA; Gerhard-Herman, M; Gordon, CM; Gordon, LB; Greer, MM; Huh, SY; Kieran, MW; Kleinman, ME; Liang, MG; Littlefield, K; Massaro, J; Miller, DT; Nazarian, A; Quinn, N; Shappell, H; Silvera, VM; Smoot, LB; Snyder, BD; Ullrich, NJ | 1 |
| Lempp, FA; Ni, Y; Urban, S | 1 |
| Barreiro, P; Sherman, KE; Soriano, V | 1 |
| Elazar, M; Glenn, JS | 1 |
| Gonzalez, CG; Hernandez, JA; Quintana, AM | 1 |
| Rizzetto, M | 1 |
| Bozdayi, AM; Çalişkan, A; Glenn, JS; Heller, T; Idilman, R; Kalkan, Ç; Karakaya, F; Karatayli, E; Karatayli, S; Keskin, O; Koh, C; Yurdaydin, C | 1 |
| Baek, A; Cho, Y; Choi, Y; Kim, D; Kumar, R; Lee, G; Lee, KW; Park, C; Park, SJ; Park, Y; Rampogu, S; Son, M; Zeb, A | 1 |
| Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, JM; Moses, MA | 1 |
| Etzion, O | 1 |
| Chicre Bandeira de Melo, P; Grana, AG; Moura Filho, FR; Rodrigues Ferreira Rocha de Alencar, R; Silva, AA | 1 |
| Gao, L; He, C; Qiao, J; Sun, Y; Zheng, W | 1 |
| Brazier, J; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J; Shappell, H | 1 |
| Bram, Y; Chiriboga, L; Cullen, J; Frankel, AS; Gerges, S; Giersch, K; Heller, B; Hrebikova, G; Huang, T; Johnson, H; Low, BE; Lutgehetmann, M; Nahass, RG; Pais, MA; Ploss, A; Schwartz, RE; Sellau, J; Seneca, K; Sharon, Y; Shirvani-Dastgerdi, E; Toettcher, JE; Wiles, MV; Winer, BY | 1 |
| Yurdaydin, C | 1 |
| Boctor, D; Cerovac, V; Cuervo, AM; Diaz, A; Fisher, SK; Giroux, M; Goate, AM; Guzman, E; Haggarty, SJ; Hernandez, I; Hinman, CR; Kang, AA; Karch, CM; Kaushik, S; Kosik, KS; Luna, G; Rauch, JN; Reis, SA; Sibih, YE; Storm, NJ; Zekanowski, C; Zhou, H | 1 |
| Abbas, Z; Buti, M; Cornberg, M; Esteban, R; Etzion, O; Gane, EJ; Gish, RG; Glenn, JS; Hamid, S; Heller, T; Koh, C; Lampertico, P; Lurie, Y; Manns, M; Parana, R; Rizzetto, M; Urban, S; Wedemeyer, H; Yurdaydin, C | 1 |
| Adami, V; Anelli, V; Gatto, P; Mione, MC; Pancher, M; Precazzini, F; Tushe, A | 1 |
| Jin, ZG; Xu, S | 1 |
| Baltrusaitis, K; Braddock, DT; Cleveland, RH; D'Agostino, RB; Gordon, CM; Gordon, LB; Kieran, MW; Kleinman, ME; Li, X; Liang, MG; Massaro, J; Snyder, B; Walters, M | 1 |
| Bruno, IG; Cooke, JP; Lai, TP; Li, Y; Shay, JW; Sho, S; Tedone, E; Zhang, N; Zhou, G | 1 |
| Da, BL; Glenn, JS; Koh, C | 1 |
| Ankri, S; Debnath, A; Rodriguez, MA | 1 |
| Chen, D; Huang, Y; Lian, Y; Wang, J; Wei, H; Zeng, G | 1 |
| Han, Z; Liang, CG; Ma, YZ; Wang, DH; Wang, XY; Zhou, CJ | 1 |
| Gilman, C; Heller, T; Koh, C | 1 |
| Deterding, K; Wedemeyer, H | 1 |
| Caviglia, GP; Ibadullaeva, N; Ismoilov, U; Joldasova, E; Khikmatullaeva, A; Khodjaeva, M; Musabaev, E; Rizzetto, M; Said, S; Shahnoza, A | 1 |
| Caviglia, GP; Rizzetto, M | 1 |
| Eşkazan, AE; Özgür Yurttaş, N | 1 |
| Cabral, WA; Collins, FS; Cubria, MB; DuBose, A; Erdos, MR; Kamalapathy, P; Karim, L; Masoudi, A; Nazarian, A; Oftadeh, R; Snyder, BD; Suarez, S | 1 |
| Boumber, Y; Fazliyeva, R; Khazak, V; Kolenko, VM; Makhov, P; Serebriiskii, IG; Sohn, JA; Uzzo, RG | 1 |
| Aschenbrenner, DS | 1 |
| Dhillon, S | 1 |
| Macicior, J; Marcos-Ramiro, B; Ortega-Gutiérrez, S | 1 |
| Arnold, R; Djabali, K; Randl, H; Vehns, E | 1 |
| Lee, AU; Lee, C | 1 |
| Apelian, D; Bozdayi, AM; Çalişkan, A; Choong, I; Glenn, JS; Heller, T; Idilman, R; Kalkan, Ç; Karakaya, F; Karatayli, E; Karatayli, S; Keskin, O; Koh, C; Önem, S; Yurdaydin, C; Yurdcu, E | 1 |
| Cornberg, M; Dietz, CA | 1 |
| Edney, B; Kim, Y; Kondapaneni, RV; Nakod, PS; Rao, SS | 1 |
| Chefo, S; Doan, J; Donohue, K; Jeng, LJB; Joffe, HV; Joseph, DB; Li, RJ; Li, X; Ma, L; Pacanowski, M; Price, D; Shroff, H; Smpokou, P; Suzuki, M; Wang, J; Wang, Y; Yang, Y; Zhang, K; Zhang, X; Zheng, N | 1 |
| Braddock, DT; Gordon, LB; Humphrey, JD; Kawamura, Y; Li, DS; Mikush, N; Murtada, SI; Ramachandra, AB; Ren, P; Tellides, G; Wang, M | 1 |
43 review(s) available for lonafarnib and piperidines
| Article | Year |
|---|---|
[New anticancer molecules: drugs for tomorrow?].
Topics: Alkyl and Aryl Transferases; Antibodies, Monoclonal; Antineoplastic Agents; Enzyme Inhibitors; Farnesyltranstransferase; Forecasting; Oligonucleotides, Antisense; Piperidines; Protein Kinase Inhibitors; Pyridines | 1999 |
Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Binding Sites; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Molecular Structure; Neoplasms; Piperidines; Protein Conformation; Pyridines | 2001 |
Current status of clinical trials of farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Neoplasms; Piperidines; Pyridines; Quinolones; Signal Transduction | 2001 |
Farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2001 |
Farnesyl transferase inhibitors as anticancer agents.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Neoplasms; Piperidines; Pyridines; Quinolones; Tumor Cells, Cultured | 2002 |
Agents targeting ras signaling pathway.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Benzodiazepines; Enzyme Inhibitors; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Imidazoles; MAP Kinase Kinase Kinases; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; Piperidines; Proto-Oncogene Proteins c-raf; Pyridines; Quinolones; Signal Transduction | 2002 |
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Piperidines; Pyridines; Quinolones | 2003 |
Farnesyl transferase inhibitors in the treatment of breast cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2003 |
Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Binding Sites; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Molecular Structure; Neoplasms; Piperidines; Protein Conformation; Pyridines | 2003 |
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Piperidines; Protein Prenylation; Proto-Oncogene Mas; Pyridines; Quinolones; ras Proteins; Signal Transduction | 2003 |
[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides | 2004 |
Novel agents and incremental advances in the treatment of head and neck cancer.
Topics: Adenoviridae; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Genes, p53; Head and Neck Neoplasms; Humans; Piperidines; Pyridines; ras Proteins; Viral Vaccines | 2004 |
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins; Signal Transduction | 2004 |
[Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Farnesyltranstransferase; Genes, ras; GTP-Binding Proteins; Guanosine Triphosphate; Humans; Imidazoles; Neoplasms; Piperidines; Point Mutation; Pyridines; Quinolones; Signal Transduction | 2004 |
[Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Topics: Alkyl and Aryl Transferases; Benzodiazepines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 1; Myeloproliferative Disorders; Piperidines; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Quinolones; ras Proteins; rho GTP-Binding Proteins | 2005 |
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mevalonic Acid; Neoplasms; Phosphatidylinositol 3-Kinases; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; ras Proteins | 2005 |
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Acute Disease; Aged; Alkyl and Aryl Transferases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Remission Induction; Signal Transduction; Treatment Outcome | 2005 |
Development of farnesyl transferase inhibitors: a review.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2005 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
[Farnesyl transferase inhibitors--a novel agent for breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Piperidines; Protein Prenylation; Pyridines; Quinolones; ras Proteins | 2006 |
Lonafarnib in cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Lung Neoplasms; Piperidines; Pyridines; Randomized Controlled Trials as Topic | 2006 |
Farnesyltransferase inihibitors in hematologic malignancies.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Piperidines; Pyridines; Quinolones; Signal Transduction | 2007 |
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Farnesyltranstransferase; Gastrointestinal Diseases; Genes, ras; Hematologic Neoplasms; Humans; Middle Aged; Myelodysplastic Syndromes; Piperidines; Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Treatment Outcome | 2006 |
Lonafarnib for cancer and progeria.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Progeria; Protein Prenylation; Pyridines; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Topics: Antineoplastic Agents; Biological Products; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Pyridines; Quantitative Structure-Activity Relationship; Quinolones | 2013 |
Progeria: a rare genetic premature ageing disorder.
Topics: Aging; Child; Clinical Trials as Topic; Humans; Lamin Type A; Longevity; Mutation; Piperidines; Prenylation; Progeria; Pyridines; Rare Diseases | 2014 |
Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
Topics: Animals; Antiviral Agents; Cells, Cultured; Disease Models, Animal; Hepatitis D, Chronic; Hepatitis Delta Virus; Host-Pathogen Interactions; Humans; Interferon-alpha; Lipopeptides; Nucleic Acids; Piperidines; Pyridines; Virus Replication | 2016 |
Hepatitis delta and HIV infection.
Topics: Antiviral Agents; Disease Transmission, Infectious; Hepatitis D, Chronic; HIV Infections; Humans; Interferon-alpha; Lipopeptides; Liver Cirrhosis; Liver Neoplasms; Piperidines; Pyridines; Sustained Virologic Response | 2017 |
Emerging concepts for the treatment of hepatitis delta.
Topics: Animals; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis D; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Liver Cirrhosis; Liver Neoplasms; Mice; Piperidines; Pyridines | 2017 |
Investigational drugs in development for Hepatitis D.
Topics: Animals; Antiviral Agents; Drug Design; Drug Therapy, Combination; Drugs, Investigational; Hepatitis B virus; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferons; Lipopeptides; Piperidines; Pyridines | 2017 |
New treatment options for delta virus: Is a cure in sight?
Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Interleukins; Lipopeptides; Nucleic Acids; Piperidines; Polyethylene Glycols; Polymers; Pyridines | 2019 |
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
Topics: Biomarkers; Clinical Trials as Topic; Hepatitis B Surface Antigens; Hepatitis D, Chronic; Humans; Lipopeptides; Liver; Nucleic Acids; Piperidines; Polymers; Pyridines; RNA, Viral; Treatment Outcome | 2019 |
Hutchinson-Gilford Progeria Syndrome: Cardiovascular Pathologies and Potential Therapies.
Topics: Cardiovascular Diseases; Humans; Piperidines; Progeria; Pyridines | 2019 |
HBV/HDV Coinfection: A Challenge for Therapeutics.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Coinfection; Drugs, Investigational; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Male; Piperidines; Polyethylene Glycols; Prognosis; Pyridines; Recombinant Proteins; Risk Assessment; Treatment Outcome | 2019 |
Chronic hepatitis delta: A state-of-the-art review and new therapies.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Global Burden of Disease; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Organic Anion Transporters, Sodium-Dependent; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Review Literature as Topic; Superinfection; Symporters; Therapies, Investigational; Treatment Outcome; Virus Assembly; Virus Internalization | 2019 |
Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Drug-Related Side Effects and Adverse Reactions; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Nucleic Acids; Piperidines; Polymers; Pyridines; Recurrence; Treatment Outcome | 2019 |
Treatment of hepatitis D: an unmet medical need.
Topics: Antiviral Agents; Drug Development; Drug Synergism; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Nucleic Acids; Piperidines; Polymers; Pyridines | 2020 |
Novel therapeutic approaches in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Everolimus; Fusion Proteins, bcr-abl; Gene Expression; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Niacinamide; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinolones; Recombinant Proteins | 2020 |
Lonafarnib: First Approval.
Topics: Antiviral Agents; Enzyme Inhibitors; Farnesyltranstransferase; Hepatitis D; Humans; Piperidines; Progeria; Pyridines | 2021 |
Small-Molecule Therapeutic Perspectives for the Treatment of Progeria.
Topics: Aging; Aging, Premature; Cell Nucleus; Cellular Senescence; Fibroblasts; Humans; Lamin Type A; Laminopathies; Mutation; Nuclear Lamina; Phenotype; Piperidines; Progeria; Pyridines; Skin; Small Molecule Libraries | 2021 |
Hepatitis D Review: Challenges for the Resource-Poor Setting.
Topics: Antiviral Agents; Drug Therapy, Combination; Europe; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis D; Humans; Interferon-alpha; Lipopeptides; Piperidines; Pyridines; Treatment Outcome; Viral Load; Virus Replication | 2021 |
33 trial(s) available for lonafarnib and piperidines
| Article | Year |
|---|---|
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antineoplastic Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lamin Type A; Lamins; Male; Middle Aged; Mouth Mucosa; Neoplasms; Nuclear Proteins; Piperidines; Protein Precursors; Pyridines | 2000 |
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Piperidines; Pyridines | 2001 |
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperidines; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperidines; Pyridines | 2002 |
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Heart Arrest; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperidines; Pyridines; Treatment Outcome | 2004 |
Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Farnesyltranstransferase; Humans; Leukemia, Myelomonocytic, Chronic; Leukocytosis; Male; Middle Aged; Piperidines; Pyridines; Radiography, Thoracic | 2005 |
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Farnesyltranstransferase; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Pyridines; Salvage Therapy; Survival Analysis; Urologic Neoplasms | 2005 |
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Piperidines; Pyridines; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Farnesyltranstransferase; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Piperidines; Pyridines; Pyrimidines | 2006 |
[Farnesyl transferase inhibitors--a novel agent for breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Piperidines; Protein Prenylation; Pyridines; Quinolones; ras Proteins | 2006 |
Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Piperidines; Pyridines; Time Factors | 2007 |
Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function.
Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; Chromosomes, Human; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Head and Neck Neoplasms; Humans; Kinetochores; Metaphase; Microfilament Proteins; Microtubules; Piperidines; Prometaphase; Protein Kinases; Protein Serine-Threonine Kinases; Pyridines; Spindle Apparatus | 2007 |
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Piperidines; Pyridines; Pyrimidines; Treatment Failure; Treatment Outcome; Vomiting | 2007 |
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Cons
Topics: Administration, Oral; Adolescent; Adult; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Piperidines; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
Topics: Adult; Aged; Analysis of Variance; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasms; Piperidines; Pyridines | 2007 |
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Gemcitabine; HSP40 Heat-Shock Proteins; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Piperidines; Pyridines; Treatment Outcome; Vomiting | 2008 |
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Drug Monitoring; Enzyme Inhibitors; Farnesyltranstransferase; Gastrointestinal Diseases; Humans; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Piperidines; Pyridines; Remission Induction; Treatment Outcome | 2008 |
Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
Topics: Aged; Farnesyltranstransferase; Female; Gastrointestinal Diseases; Genes, ras; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Piperidines; Pyridines | 2008 |
A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperidines; Prognosis; Pyridines; Survival Rate; Treatment Outcome | 2009 |
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Area Under Curve; Enzyme Inhibitors; Female; Humans; Lamin Type A; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Nuclear Proteins; Piperidines; Protein Precursors; Pyridines; Treatment Outcome | 2011 |
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Piperidines; Pyridines; Taxoids | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazine; Disease-Free Survival; Drug Combinations; Enzyme Inhibitors; Fatty Acids, Unsaturated; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Piperidines; Pyridines; Temozolomide; Vitamin E | 2011 |
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Piperidines; Pyridines | 2011 |
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Prospective Studies; Pyridines; Survival Analysis; Young Adult | 2012 |
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
Topics: Adolescent; Carotid Arteries; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Piperidines; Progeria; Pulse Wave Analysis; Pyridines; Treatment Outcome; Vomiting; Weight Gain | 2012 |
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Piperidines; Pyridines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperidines; Pyridines; Supratentorial Neoplasms; Temozolomide | 2013 |
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Male; Nervous System Diseases; Piperidines; Progeria; Pyridines; Retrospective Studies; Treatment Outcome | 2013 |
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carboplatin; Farnesyltranstransferase; Female; Genetic Markers; Genotype; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Piperidines; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Subunits; Pyridines; Treatment Outcome; Young Adult | 2015 |
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Male; Middle Aged; Piperidines; Placebos; Plasma; Prenylation; Pyridines; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
Topics: Bone and Bones; Carotid Arteries; Child, Preschool; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Infant; Male; Piperidines; Pravastatin; Progeria; Prospective Studies; Protein Prenylation; Pyridines; Zoledronic Acid | 2016 |
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Piperidines; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Young Adult | 2018 |
A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
Topics: Alanine Transaminase; Drug Therapy, Combination; Hepatitis D, Chronic; HIV Infections; Humans; Interferon-alpha; Piperidines; Pyridines; Ritonavir; RNA | 2022 |
115 other study(ies) available for lonafarnib and piperidines
| Article | Year |
|---|---|
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Topics: 3T3 Cells; Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bromodeoxyuridine; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Genes, ras; Humans; Macaca fascicularis; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Piperidines; Pyridines; Rats; Transplantation, Heterologous | 1998 |
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; COS Cells; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Macaca fascicularis; Mice; Mice, Nude; Piperidines; Protein Prenylation; Pyridines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 1998 |
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Topics: Alkyl and Aryl Transferases; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Piperidines; Pyridines; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Binding Sites; Calorimetry; Crystallography, X-Ray; Cyclic N-Oxides; Enzyme Inhibitors; Heterocyclic Compounds, 3-Ring; Hydrogen Bonding; Models, Molecular; Piperidines; Protein Prenylation; Pyridines; Thermodynamics | 1999 |
High-performance liquid chromatographic analysis of the anti-tumor agent SCH 66336 in cynomolgus monkey plasma and evaluation of its chiral inversion in animals.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Macaca fascicularis; Male; Piperidines; Pyridines; Rats; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stereoisomerism | 1999 |
Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H-benzo[5,6]-cyclo hepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N-oxide as inhibitors of farnesyl protein transferase.
Topics: Alkyl and Aryl Transferases; Enzyme Inhibitors; Inhibitory Concentration 50; Piperidines; Pyridines | 1999 |
Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Biological Availability; Cell Division; COS Cells; Enzyme Inhibitors; Haplorhini; Mice; Mice, Nude; Piperidines; Protein Prenylation; Proto-Oncogene Proteins p21(ras); Pyridines; Structure-Activity Relationship; Sulfonamides; Sulfonylurea Compounds | 1999 |
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Topics: Adenocarcinoma; Adenoviruses, Human; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Drug Synergism; Female; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, SCID; Mice, Transgenic; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Pyridines; Teratocarcinoma; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules.
Topics: Alkyl and Aryl Transferases; Cell Cycle; Chromosomal Proteins, Non-Histone; Enzyme Inhibitors; Humans; Mevalonic Acid; Microfilament Proteins; Microtubule-Associated Proteins; Microtubules; Piperidines; Protein Prenylation; Pyridines; Substrate Specificity; Tumor Cells, Cultured | 2000 |
Comparison of potential markers of farnesyltransferase inhibition.
Topics: Alkyl and Aryl Transferases; Amino Acid Sequence; Antineoplastic Agents; Biomarkers, Tumor; Carrier Proteins; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Farnesyltranstransferase; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Lamin Type A; Lamins; Methionine; Molecular Sequence Data; Nuclear Proteins; Peptides; Piperidines; Protein Precursors; Protein Prenylation; Pyridines; Signal Transduction; Transfection; Tumor Cells, Cultured | 2000 |
Enzymatic kinetic resolution of piperidine atropisomers: synthesis of a key intermediate of the farnesyl protein transferase inhibitor, SCH66336.
Topics: Acylation; Alkyl and Aryl Transferases; Enzyme Inhibitors; Kinetics; Piperidines; Pyridines; Spectrum Analysis; Stereoisomerism | 2000 |
The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Cell Cycle; Cell Division; Cell Membrane; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Farnesyltranstransferase; G1 Phase; G2 Phase; Humans; K562 Cells; Kinetics; Mice; Mitosis; Molecular Structure; Oncogene Protein p21(ras); Piperidines; Pyridines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Docetaxel; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, Transgenic; Paclitaxel; Piperidines; Pyridines; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Marrow; Farnesyltranstransferase; Genes, abl; Mice; Mice, Transgenic; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate | 2001 |
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Cycle; Cell Division; Enzyme Inhibitors; Farnesyltranstransferase; Genes, abl; Hematopoietic Stem Cells; Humans; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperidines; Pyridines; Spleen; Survival Rate; Transformation, Genetic; Tumor Cells, Cultured | 2001 |
Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
Topics: Alkyl and Aryl Transferases; Cell Division; Cell Survival; Enzyme Inhibitors; Farnesyltranstransferase; G2 Phase; Glioblastoma; Humans; Mitogen-Activated Protein Kinases; Piperidines; Pyridines; Tumor Cells, Cultured | 2000 |
Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Cell Cycle; Cisplatin; DNA Adducts; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Melphalan; Piperidines; Platinum; Pyridines; Tumor Cells, Cultured | 2001 |
Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
Topics: Alkyl and Aryl Transferases; Animals; Astrocytoma; Brain Neoplasms; Cell Division; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Glioblastoma; Guanosine Triphosphate; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Monomeric GTP-Binding Proteins; Mutation; Piperidines; Pyridines; ras Proteins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; CHO Cells; Cricetinae; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Genes, MDR; Humans; Hydrolysis; Mice; Paclitaxel; Piperidines; Pyridines; Rhodamine 123; Tamoxifen; Vinblastine | 2001 |
An anion-induced regio- and chemoselective acylation and its application to the synthesis of an anticancer agent.
Topics: Acylation; Antineoplastic Agents; Cyclization; Indicators and Reagents; Ketones; Piperidines; Pyridines | 2001 |
Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Topics: Alkyl and Aryl Transferases; Animals; Apoptosis; Butadienes; Cell Line; Cell Line, Transformed; Enzyme Inhibitors; Fibroblasts; Flavonoids; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Piperidines; Protein Prenylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Pyridines; Rats | 2002 |
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines | 2002 |
Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitor
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bromine; Crystallography, X-Ray; Enzyme Inhibitors; Half-Life; Indoles; Mice; Mice, Nude; Models, Molecular; Piperidines; Pyridines; Structure-Activity Relationship; Thermodynamics | 2002 |
Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Piperidines; Pyridines; Quinolones | 2002 |
Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; COS Cells; Enzyme Inhibitors; Kidney; Models, Molecular; Piperidines; Pyridines; Solubility; Structure-Activity Relationship; Tritium | 2003 |
Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line.
Topics: Alkyl and Aryl Transferases; Apoptosis; Benzamides; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Piperidines; Pyridines; Pyrimidines; Research Design; Tumor Cells, Cultured | 2003 |
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured | 2003 |
Overcoming resistance to imatinib by combining targeted agents.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Pyridines; Pyrimidines | 2003 |
Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Topics: 3T3 Cells; Actins; Alkyl and Aryl Transferases; Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Cisplatin; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Farnesol; Farnesyltranstransferase; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Melanoma; Mice; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Retinoblastoma Protein; Salicylates; Skin Neoplasms; Tumor Cells, Cultured | 2003 |
A novel enantioselective alkylation and its application to the synthesis of an anticancer agent.
Topics: Alkylation; Antineoplastic Agents; Catalysis; Combinatorial Chemistry Techniques; Indicators and Reagents; Molecular Structure; Piperidines; Pyridines; Stereoisomerism | 2003 |
Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
Topics: Alkyl and Aryl Transferases; Apoptosis; bcl-X Protein; Carcinoma, Squamous Cell; Enzyme Inhibitors; Farnesyltranstransferase; Head and Neck Neoplasms; Humans; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Tumor Cells, Cultured | 2003 |
High-performance liquid chromatography-atmospheric pressure photoionization/tandem mass spectrometric analysis for small molecules in plasma.
Topics: Administration, Oral; Animals; Atmospheric Pressure; Chromatography, High Pressure Liquid; Clozapine; Drug Evaluation, Preclinical; Drugs, Investigational; Mass Spectrometry; Photochemistry; Piperidines; Pyridines; Rats | 2003 |
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperidines; Pyridines; Quinolones | 2003 |
A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Farnesyltranstransferase; Female; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Nude; Mice, Transgenic; Piperazines; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Survival Rate; Tumor Cells, Cultured | 2004 |
The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cisplatin; Cyclophosphamide; Drug Interactions; Drug Resistance, Multiple; Flow Cytometry; Fluorouracil; Humans; Piperidines; Pyridines | 2003 |
In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Topics: Alkyl and Aryl Transferases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Piperidines; Pyridines | 2004 |
Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis.
Topics: Active Transport, Cell Nucleus; Alkyl and Aryl Transferases; Apoptosis; Blotting, Western; Carcinogens; Cell Division; Cell Line, Tumor; Cell Survival; Cytoplasm; DNA; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; I-kappa B Kinase; Immunohistochemistry; In Situ Nick-End Labeling; Inflammation; Jurkat Cells; Models, Chemical; Neovascularization, Pathologic; NF-kappa B; Okadaic Acid; Phosphorylation; Piperidines; Protein Binding; Protein Serine-Threonine Kinases; Pyridines; ras Proteins; Smoking; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2004 |
Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator.
Topics: Animals; Cell Division; Cell Line; CHO Cells; Cricetinae; Drug Design; Enzyme Inhibitors; Kinetics; Mitogen-Activated Protein Kinases; Molecular Structure; Piperidines; Pyridines; ras Proteins; Recombinant Proteins; Signal Transduction; Structure-Activity Relationship | 2004 |
The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Topics: Alkyl and Aryl Transferases; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cattle; Cell Cycle; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Serum Albumin, Bovine; Signal Transduction; Tumor Cells, Cultured | 2004 |
The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
Topics: Adrenergic beta-Agonists; Alkyl and Aryl Transferases; Amino Acid Motifs; Animals; Calcium Signaling; Carrier Proteins; Cell Line; Cell Line, Tumor; Cyclic AMP; Dose-Response Relationship, Drug; Endocytosis; Epoprostenol; Farnesyltranstransferase; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Iloprost; Isoproterenol; Kidney; Leukemia, Erythroblastic, Acute; Mice; Mutagenesis, Site-Directed; Organophosphorus Compounds; Piperidines; Proline; Propanolamines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Receptors, Adrenergic, beta-2; Receptors, Epoprostenol; Receptors, Thromboxane A2, Prostaglandin H2; Recombinant Fusion Proteins; Signal Transduction; Transfection | 2005 |
Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Topics: Adenoviridae; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Products, tat; Genes, ras; Genetic Vectors; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; MAP Kinase Kinase 1; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Piperidines; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; ras Proteins; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
Topics: Alkyl and Aryl Transferases; Carcinoma; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Culture Media; Dose-Response Relationship, Drug; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Farnesyltranstransferase; Fibrinolysin; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Kinetics; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Piperidines; Plasminogen; Protein Isoforms; Proto-Oncogene Proteins p21(ras); Pyridines; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator | 2005 |
Farnesyltransferase inhibition: who are the Aktors?
Topics: Alkyl and Aryl Transferases; Apoptosis; Cell Cycle; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction | 2004 |
Hit to Lead Success Stories--IBC Conference: Effective chemistry strategies for reducing attrition rates and speeding lead compounds into the pipeline. 31 January-1 February 2005, San Diego, CA, USA.
Topics: Aniline Compounds; Bradykinin; Drug Approval; Drug Design; Drug Evaluation; Humans; Molecular Structure; Piperidines; Propionates; Pyridines; Time Factors | 2005 |
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Topics: Acetylation; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Synergism; Farnesyltranstransferase; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Mice; Microtubules; Mitosis; NIH 3T3 Cells; Paclitaxel; Piperidines; Pyridines; Tubulin | 2005 |
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin | 2005 |
Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamid
Topics: Alkyl and Aryl Transferases; Carcinoma; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; HCT116 Cells; Humans; Piperidines; Pyridines | 2005 |
Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells.
Topics: Alkyl and Aryl Transferases; Amino Acid Sequence; Carcinoma, Squamous Cell; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Farnesyltranstransferase; Head and Neck Neoplasms; Humans; MAP Kinase Signaling System; Molecular Sequence Data; Neoplasm Proteins; Peptide Elongation Factor 2; Phosphorylation; Piperidines; Protein Synthesis Inhibitors; Pyridines | 2005 |
Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Injections, Intravenous; Molecular Structure; Paclitaxel; Piperidines; Pyridines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Trastuzumab | 2005 |
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bridged-Ring Compounds; Caspases; Cell Line, Tumor; Farnesyltranstransferase; Humans; Monomeric GTP-Binding Proteins; Neoplasms; Neuropeptides; Phosphorylation; Piperidines; Protein Kinases; Protein Prenylation; Pyridines; Ras Homolog Enriched in Brain Protein; Recombinant Fusion Proteins; RNA, Messenger; Signal Transduction; Tamoxifen; Taxoids; TOR Serine-Threonine Kinases | 2005 |
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
Topics: Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Phosphorylation; Piperidines; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured | 2005 |
Novel 2,2-bipyridine ligand for palladium-catalyzed regioselective carbonylation.
Topics: Antineoplastic Agents; Catalysis; Indicators and Reagents; Ligands; Palladium; Piperidines; Pyridines | 1999 |
Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Immunoprecipitation; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Piperidines; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Ubiquitin; Up-Regulation; Vascular Endothelial Growth Factor A | 2005 |
Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
Topics: Animals; Aorta; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Chickens; Chorioallantoic Membrane; Endothelium, Vascular; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 3; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyridines; rhoB GTP-Binding Protein; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor A | 2006 |
Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar).
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Ketoconazole; Microsomes, Liver; Oxidation-Reduction; Piperidines; Pyridines; Recombinant Proteins | 2006 |
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Imidazoles; Indoles; Mevalonic Acid; Multiple Myeloma; Piperidines; Pyridines; Structure-Activity Relationship; Zoledronic Acid | 2007 |
Identification of unstable metabolites of Lonafarnib using liquid chromatography-quadrupole time-of-flight mass spectrometry, stable isotope incorporation and ion source temperature alteration.
Topics: Carbon Isotopes; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Stability; Humans; Ions; Isotope Labeling; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Piperidines; Pyridines; Temperature | 2006 |
A generalized response surface model with varying relative potency for assessing drug interaction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biometry; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Antagonism; Drug Interactions; Drug Synergism; Fenretinide; Humans; Models, Biological; Models, Statistical; Piperidines; Pyridines | 2006 |
Exploring three-dimensional quantitative structural activity relationship (3D-QSAR) analysis of SCH 66336 (Sarasar) analogues of farnesyltransferase inhibitors.
Topics: Drug Evaluation, Preclinical; Farnesyltranstransferase; Least-Squares Analysis; Models, Molecular; Molecular Conformation; Piperidines; Pyridines; Quantitative Structure-Activity Relationship; Regression Analysis; Reproducibility of Results | 2008 |
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Topics: Apoptosis; Caspase 8; Cell Line, Tumor; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Piperidines; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Up-Regulation | 2007 |
Farnesyl transferase inhibitor resistance probed by target mutagenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutagenesis; Mutagenesis, Site-Directed; Mutation; Pilot Projects; Piperazines; Piperidines; Protein Conformation; Protein Prenylation; Pyridines; Pyrimidines; Tumor Cells, Cultured | 2007 |
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
Topics: Antibodies, Monoclonal; Blotting, Western; CD28 Antigens; CD3 Complex; Cells, Cultured; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; HSP40 Heat-Shock Proteins; Humans; Interferon-gamma; Interleukin-2; Interleukin-4; Lymphocyte Activation; MAP Kinase Kinase 4; Methionine; Phosphorylation; Piperidines; Protein Prenylation; Pyridines; Quinolones; Ribonuclease, Pancreatic; Ribosomal Protein S6 Kinases, 70-kDa; RNA Processing, Post-Transcriptional; T-Lymphocytes; Th1 Cells; Th2 Cells | 2007 |
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Ovariectomy; Piperidines; Pyridines; S Phase; Tamoxifen; Triazoles | 2007 |
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colorimetry; Drug Synergism; Flow Cytometry; Humans; Indicators and Reagents; Lapatinib; Mutation; Oncogene Protein v-akt; Piperidines; Prenylation; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2008 |
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Female; HSP40 Heat-Shock Proteins; Humans; Leukocytes, Mononuclear; Mice; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Piperidines; Pyridines; Xenograft Model Antitumor Assays | 2008 |
Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperidines; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survivin; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2008 |
Mass spectrometric studies of potent inhibitors of farnesyl protein transferase--detection of pentameric noncovalent complexes.
Topics: Alkyl and Aryl Transferases; Chromatography, Gel; Enzyme Inhibitors; Mass Spectrometry; Molecular Weight; Piperidines; Protein Denaturation; Pyridines; Spectrometry, Mass, Electrospray Ionization | 2008 |
Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Flow Cytometry; Lymphocytes; Lymphoma, B-Cell; Methionine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Piperidines; Pyridines; Remission Induction | 2008 |
Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
Topics: Animals; Antibiotics, Antineoplastic; Blotting, Western; Cell Transformation, Neoplastic; Cells, Cultured; Cellular Senescence; Doxorubicin; Eukaryotic Initiation Factor-4E; Farnesyltranstransferase; Female; Fibroblasts; Gene Dosage; Humans; Immunophenotyping; Immunosuppressive Agents; Lymphoma; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Mice, Knockout; Monomeric GTP-Binding Proteins; Multiprotein Complexes; Neuropeptides; Phosphorylation; Piperidines; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Pyridines; Ras Homolog Enriched in Brain Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Protein p53 | 2008 |
Autophagy induced by farnesyltransferase inhibitors in cancer cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Pancreatic Neoplasms; Piperidines; Polyenes; Polyunsaturated Alkamides; Protein Kinases; Pyridines; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2008 |
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase 6; Histone Deacetylases; Humans; Microtubules; Models, Biological; Paclitaxel; Piperidines; Pyridines; Time Factors | 2009 |
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Hormone-Dependent; Piperidines; Prostatic Neoplasms; Pyridines; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |
[Targeting KRAS pathway in NSCLC therapy].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib | 2009 |
Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.
Topics: Alkyl and Aryl Transferases; Animals; Cell Line, Tumor; Cell Proliferation; Dimethylallyltranstransferase; Farnesyltranstransferase; Fibroblasts; Humans; Imidazoles; Inhibitory Concentration 50; Leucine; Mice; Mutation; Piperidines; Pyridines; ras Proteins; Transfection | 2011 |
Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Monomeric GTP-Binding Proteins; Multiprotein Complexes; Mutation; Neuropeptides; Phosphorylation; Piperidines; Prenylation; Proteins; Pyridines; Quinolones; Ras Homolog Enriched in Brain Protein; Ribosomal Protein S6; RNA Interference; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Transfection | 2010 |
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Benzenesulfonates; Cell Line, Tumor; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factor CHOP | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Mice; Neoplasm Transplantation; Piperidines; Prenylation; Pyridines; Radiation, Ionizing; ras Proteins; Signal Transduction; Temozolomide; Time Factors | 2011 |
The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.
Topics: Acyclic Monoterpenes; Alendronate; Animals; Anti-Inflammatory Agents; Cell Line; Child; Child, Preschool; Cholesterol; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Inflammation Mediators; Lovastatin; Male; Mevalonate Kinase Deficiency; Mice; Monocytes; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Polyenes; Polyisoprenyl Phosphates; Polyunsaturated Alkamides; Pyridines; Quinolones; Terpenes | 2011 |
A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Farnesyltranstransferase; Female; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 3; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, IGF Type 1; RNA Interference; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Urokinase-Type Plasminogen Activator | 2012 |
Medicine. Drug trial offers uncertain start in race to save children with progeria.
Topics: Animals; Child, Preschool; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Foundations; Humans; Lamin Type A; Mice; Mutation; Patient Selection; Piperidines; Progeria; Pyridines; Uncertainty; United States; United States Public Health Service | 2012 |
New cures sought from old drugs.
Topics: Child; Crowdsourcing; Drug Repositioning; Humans; National Institutes of Health (U.S.); Piperidines; Progeria; Pyridines; United States | 2012 |
Drug development for progeria yields insights into normal aging.
Topics: Aging; Child; Clinical Trials as Topic; Diphosphonates; Drug Discovery; Humans; Imidazoles; Lamin Type A; Mutation; Piperidines; Pravastatin; Progeria; Pyridines; Time Factors; Zoledronic Acid | 2013 |
Moving from gene discovery to clinical trials in Hutchinson-Gilford progeria syndrome.
Topics: Female; Humans; Male; Nervous System Diseases; Piperidines; Progeria; Pyridines | 2013 |
Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Cell Line, Tumor; Enzyme Inhibitors; Farnesyltranstransferase; Gene Dosage; Gene Knock-In Techniques; Genes, ras; Humans; Mice, Mutant Strains; Mutation; Papilloma; Piperidines; Pyridines; Skin Neoplasms; Tetradecanoylphorbol Acetate | 2014 |
Theoretical studies on binding and specificity mechanisms of farnesyltransferase (FTase) and geranylgeranyltransferase type-I (GGTase-I) inhibitors by molecular modeling.
Topics: Alkyl and Aryl Transferases; Animals; Enzyme Inhibitors; Farnesyltranstransferase; Imidazoles; Leucine; Molecular Docking Simulation; Molecular Dynamics Simulation; Naphthalenes; Piperidines; Protein Binding; Pyridines; Rats; Thermodynamics | 2014 |
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Topics: Adolescent; Adult; Alkyl and Aryl Transferases; Atherosclerosis; Cause of Death; Child; Child, Preschool; Clinical Trials as Topic; Cohort Studies; Dimethylallyltranstransferase; Diphosphonates; Drug Therapy, Combination; Female; Genes, Dominant; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Kaplan-Meier Estimate; Lamin Type A; Male; Multicenter Studies as Topic; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Proportional Hazards Models; Protein Precursors; Protein Prenylation; Pyridines; Treatment Outcome; Young Adult; Zoledronic Acid | 2014 |
An encouraging progress report on the treatment of progeria and its implications for atherogenesis.
Topics: Diphosphonates; Female; Humans; Imidazoles; Lamin Type A; Male; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Protein Precursors; Protein Prenylation; Pyridines; Zoledronic Acid | 2014 |
Lonafarnib is a potential inhibitor for neovascularization.
Topics: Alkyl and Aryl Transferases; Animals; Apolipoproteins E; Atherosclerosis; Cell Polarity; Cell Proliferation; Cytoskeletal Proteins; Endothelial Cells; Gene Expression Regulation; Humans; Mice; Neovascularization, Pathologic; Piperidines; Pyridines | 2015 |
Progeria and the early aging in children: a case report.
Topics: Aging; Body Height; Body Weight; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Infant; Lamin Type A; Piperidines; Progeria; Pyridines | 2016 |
Functional analysis of the zebrafish ortholog of HMGCS1 reveals independent functions for cholesterol and isoprenoids in craniofacial development.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Benzophenones; Body Patterning; Cell Differentiation; Cholesterol; Chondrocytes; Craniofacial Abnormalities; Embryo, Nonmammalian; Enzyme Inhibitors; Gene Expression Regulation, Developmental; Hedgehog Proteins; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Synthase; Neural Crest; Piperidines; Pyridines; Signal Transduction; Terpenes; Zebrafish; Zebrafish Proteins; Zinc Finger Protein GLI1 | 2017 |
Computational Exploration for Lead Compounds That Can Reverse the Nuclear Morphology in Progeria.
Topics: Drug Design; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Progeria; Pyridines | 2017 |
Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib.
Topics: Adolescent; beta 2-Microglobulin; Biomarkers; Blood Proteins; C-Reactive Protein; Case-Control Studies; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Interleukin-13; Interleukin-1alpha; Interleukin-7; Lamin Type A; Longitudinal Studies; Male; Mutation; Myoglobin; Piperidines; Progeria; Prospective Studies; Pyridines | 2018 |
Treatment for hepatitis delta virus with the prenylation inhibitor lonafarnib: It's getting closer.
Topics: Hepatitis Delta Virus; Piperidines; Prenylation; Pyridines | 2018 |
Progeria: case report and new drugs perspectives.
Topics: Cell Nucleus; Child, Preschool; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lamin Type A; Mutation; Piperidines; Progeria; Pyridines | 2018 |
Lonafarnib synergizes with azoles against Aspergillus spp. and Exophiala spp.
Topics: Antifungal Agents; Aspergillus; Azoles; Drug Synergism; Exophiala; Humans; Microbial Sensitivity Tests; Piperidines; Pyridines | 2018 |
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
Topics: Adolescent; Adult; Cause of Death; Child; Cohort Studies; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Lamin Type A; Male; Phosphotransferases (Phosphate Group Acceptor); Piperidines; Progeria; Protein Processing, Post-Translational; Pyridines; Young Adult | 2018 |
Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Topics: Adaptive Immunity; Animals; Disease Models, Animal; Drug Therapy, Combination; Genome, Viral; Glycoproteins; Hepatitis B virus; Hepatitis D; Hepatitis Delta Virus; Hepatocytes; Humans; Immunity, Innate; Immunocompetence; Lipopeptides; Mice, Inbred C57BL; Mice, Transgenic; Organic Anion Transporters, Sodium-Dependent; Piperidines; Pyridines; Symporters; Transgenes; Viremia | 2018 |
A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy.
Topics: Animals; Brain; Disease Models, Animal; Enzyme Inhibitors; Farnesyltranstransferase; Female; GTP-Binding Proteins; Humans; Induced Pluripotent Stem Cells; Lysosomes; Male; Mice; Mice, Transgenic; Mutation; Neurons; Piperidines; Proteolysis; Pyridines; RNA, Small Interfering; tau Proteins; Tauopathies; Translational Research, Biomedical | 2019 |
Automated in vivo screen in zebrafish identifies Clotrimazole as targeting a metabolic vulnerability in a melanoma model.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clotrimazole; Disease Models, Animal; Drug Screening Assays, Antitumor; Farnesyltranstransferase; Humans; Melanocytes; Melanoma; Melanoma, Cutaneous Malignant; Miconazole; Piperidines; Pyridines; Skin Neoplasms; Zebrafish | 2020 |
Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
Topics: Calcinosis; Calcium; Child; Child, Preschool; Creatinine; Female; Fibroblast Growth Factor-23; Humans; In Vitro Techniques; Lamin Type A; Male; Parathyroid Hormone; Piperidines; Pravastatin; Progeria; Pyridines; Zoledronic Acid | 2019 |
Transient introduction of human telomerase mRNA improves hallmarks of progeria cells.
Topics: Adolescent; Adult; Aged; Cell Line; Cellular Senescence; Child; Child, Preschool; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fibroblasts; Humans; Infant; Infant, Newborn; Lamin Type A; Male; Piperidines; Progeria; Pyridines; RNA, Messenger; Telomerase; Telomere; Telomere Homeostasis; Transfection | 2019 |
Editorial: Recent Progresses in Amebiasis.
Topics: Amebicides; Anisomycin; Asymptomatic Diseases; Drug Discovery; Dysentery, Amebic; Entamoeba histolytica; Flavonoids; Gene Expression Regulation; Humans; Life Cycle Stages; Metabolic Networks and Pathways; Metronidazole; Piperidines; Prodigiosin; Protozoan Proteins; Pyridines; Severity of Illness Index | 2019 |
The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Models, Biological; Piperidines; Protein Kinase Inhibitors; Proteolysis; Pyridines; Sorafenib; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2019 |
Loss of CENPF leads to developmental failure in mouse embryos.
Topics: Animals; Blastocyst; Centromere; Chromosomal Proteins, Non-Histone; Embryo, Mammalian; Embryonic Development; Farnesyltranstransferase; Female; Gene Knockdown Techniques; Metaphase; Mice; Mice, Inbred ICR; Microfilament Proteins; Morpholinos; Morula; Oocytes; Parthenogenesis; Piperidines; Pregnancy; Prenylation; Pyridines; Zygote | 2019 |
Hepatitis D virus in Uzbekistan.
Topics: Adult; Chronic Disease; Female; Fibrosis; Global Burden of Disease; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis D; Hepatitis Delta Virus; Humans; Incidence; Interferon-alpha; Lipopeptides; Liver Diseases; Male; Middle Aged; Piperidines; Prevalence; Pyridines; Risk Factors; Superinfection; Uzbekistan | 2020 |
Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
Topics: Aging; Animals; Bone and Bones; Bone Density Conservation Agents; Cartilage; Disease Models, Animal; Femur; Glycosaminoglycans; Joints; Lamin Type A; Mice; Mice, Transgenic; Mutation; Osteoarthritis; Phenotype; Piperidines; Pravastatin; Progeria; Protein Processing, Post-Translational; Pyridines; X-Ray Microtomography; Zoledronic Acid | 2020 |
CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; CRISPR-Cas Systems; DNA Fragmentation; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; High-Throughput Screening Assays; Humans; Kidney Neoplasms; Lysosomes; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Molecular Targeted Therapy; Neoplasm Transplantation; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Random Allocation; RNA, Small Interfering; Sunitinib | 2020 |
New Drugs for Rare Disorders.
Topics: alpha-MSH; Anti-Obesity Agents; Humans; Piperidines; Progeria; Pyridines; Rare Diseases | 2021 |
Lonafarnib.
Topics: Enzyme Inhibitors; Humans; Piperidines; Pyridines | 2021 |
Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
Topics: Adolescent; Azetidines; Cells, Cultured; Child, Preschool; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Male; Piperidines; Progeria; Purines; Pyrazoles; Pyridines; STAT1 Transcription Factor; Sulfonamides | 2021 |
Lonafarnib-A new member of the Delta Force?
Topics: Hepatitis Delta Virus; Piperidines; Pyridines | 2022 |
The impact of temozolomide and lonafarnib on the stemness marker expression of glioblastoma cells in multicellular spheroids.
Topics: Cell Line, Tumor; Dibenzocycloheptenes; Drug Resistance, Neoplasm; Endothelial Cells; Glioblastoma; Humans; Nestin; Piperidines; Pyridines; Spheroids, Cellular; Temozolomide; Tumor Microenvironment | 2022 |
FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
Topics: Humans; Lamin Type A; Piperidines; Progeria; Pyridines; United States | 2023 |
Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome.
Topics: Animals; Lamin Type A; Mice; Piperidines; Progeria; Pulse Wave Analysis; Sirolimus | 2023 |